Immunovia AB (publ) - Special Call Transcript
Ladies and gentlemen, welcome to the update on the optimization work. Today, I'm pleased to present Mats Grahn, CEO. (Operator Instructions)
Mats, please begin.
()-
Yes. Good morning, everyone. And welcome to this update. I will cover the -- shortly, about the background and then move into the investigations that we have been working with during the last 6 months and, of course, the conclusions and actions based on this.
As you all know, last year, August, we discovered and informed about the need to optimize the IMMray PanCan-d algorithms. We then also identified and informed that this was due to variations in the biobanks used for the retrospective studies. In other words, for this is pre-analytical variations, meaning, differences in the way samples have been collected and stored before the analysis using IMMray. So these pre-analytical variations are very many different parameters and that has been the focus on our investigations during the optimizations work. The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
